



Universiteit  
Leiden  
The Netherlands

## **Sexual rehabilitation after radiotherapy for gynaecological cancer**

Suvaal, I.

### **Citation**

Suvaal, I. (2026, March 5). *Sexual rehabilitation after radiotherapy for gynaecological cancer*. Retrieved from <https://hdl.handle.net/1887/4295103>


Version: Publisher's Version


License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4295103>

**Note:** To cite this publication please use the final published version (if applicable).

# Chapter 4





# **Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy: results of a randomised trial**

British Journal of Cancer, 2024; 131(5):808-819

doi: 10.1038/s41416-024-02775-8

Isabelle Suvaal

Susanna B. Hummel

Jan-Willem M. Mens

Charlotte C. Tuijnman-Raasveld

Roula Tsonaka

Laura A. Velema

Henrike Westerveld

Jeltsje S. Cnossen

An Snyers

Ina M. Jürgenliemk-Schulz

Ludy C.H.W. Lutgens

Jannet C. Beukema

Marie A.D. Haverkort

Marlies E. Nowee

Remi A. Nout

Cor D. de Kroon

Wilbert B. van den Hout

Carien L. Creutzberg

Helena C. van Doorn

Moniek M. ter Kuile

## ABSTRACT

### Objectives

The multicentre randomized SPARC trial evaluated efficacy of a nurse-led sexual rehabilitation-intervention on sexual functioning, distress, dilator use, and vaginal symptoms after radiotherapy for gynaecological cancers.

### Methods

Eligible women were randomised to the rehabilitation intervention or care-as-usual. Four intervention-sessions were scheduled over 12-months, with concurrent validated questionnaires and clinical assessments. Primary outcome was the Female Sexual Function Index (FSFI). A generalized-mixed-effects model compared groups over time.

### Results

229 women were included (n=112 intervention; n=117 care-as-usual). No differences in FSFI total-scores were found between groups at any timepoint ( $p=0.37$ ), with 12-month scores of 22.57 (intervention) versus 21.76 (care-as-usual). The intervention did not significantly improve dilator use, reduce sexual distress or vaginal symptoms compared to care-as-usual. At 12-months, both groups had minimal physician-reported vaginal stenosis; 70% of women were sexually active and reported no or mild vaginal symptoms. After radiotherapy and brachytherapy, 85% (intervention) versus 75% of participants reported dilation twice weekly.

### Conclusions

Sexual rehabilitation for women treated with combined (chemo)radiotherapy and brachytherapy improved before and during the SPARC trial, which likely contributed to comparable study groups. Best-practice involves a sexual rehabilitation-appointment one-month post-radiotherapy, including patient-information, with dilator guidance, preferable by a trained nurse, and follow-up during the first year after treatment.

## BACKGROUND

Women with locally advanced cervical and vaginal cancer are primarily treated with external beam radiotherapy with concurrent cisplatin-based chemotherapy and MRI-guided adaptive brachytherapy. Those with early stage cervical or endometrial cancer treated with upfront surgery receive adjuvant external beam radiotherapy (with or without brachytherapy boost) in case of lymph node involvement, close or involved surgical margins or a combination of risk factors. The impact of these gynaecological cancer treatments on sexual functioning can be substantial, and is more pronounced when radiotherapy is included, as compared to surgery alone<sup>1,2</sup>. Especially treatment with both external beam radiotherapy and brachytherapy has been shown to impact vaginal and sexual functioning by causing morphological changes in the vaginal mucosa, such as atrophy, adhesions, and fibrosis which may lead to vaginal stenosis and shortening<sup>3-5</sup>.

Regular vaginal dilation has been shown to help preventing and reducing vaginal stenosis<sup>6</sup>. However, many women (75%) fail to use dilators regularly, even with counselling and specific instructions<sup>7,8</sup>. Some studies suggested that additional professional support, including psycho-education and motivation, can improve compliance<sup>6</sup>, but not all studies showed such benefit<sup>9,10</sup>. In addition, reported interventions targeting dilator use did not address other psychosexual consequences of treatment of gynaecological cancer, such as sexual distress and (worries about) pain during intercourse<sup>3,7,11</sup>.

Some small studies have investigated psychosexual interventions such as cognitive-behavioural techniques, psycho-education and counselling to address sexual problems after radiotherapy<sup>5,11-13</sup>. Results indicated that such interventions can lead to improved sexual functioning, reduced sexual distress, and when the partner was actively involved, enhanced relationship satisfaction.

In a previous pilot study, a specifically developed nurse-led sexual rehabilitation intervention combining psycho-education and cognitive-behavioural therapy was shown to improve sexual functioning and compliance with dilator use in women treated with chemoradiotherapy and brachytherapy<sup>14</sup>. Subsequently a randomised trial was designed to evaluate the effectiveness of this rehabilitation intervention as compared to care-as-usual. We hypothesized that women receiving this nurse-led rehabilitation intervention would experience significantly greater improvement in sexual functioning at 12-months after radiotherapy. Additionally, we anticipated improved compliance with dilator use and fewer vaginal functioning problems and sexual distress.

## METHODS

### Study design and participants

The SPARC (Sexual rehabilitation Programme After Radiotherapy for gynaecological Cancer, NCT03611517) study was a multicentre randomised trial conducted in all 10 Dutch gynaecological oncology centres. Participating centres, including their study teams, are listed in supplementary table S1. A detailed description of the trial design has been previously reported<sup>15</sup>.

Before start of the trial, a study-specific 50-hour training programme was held, to which each participating centre sent at least two designated oncology nurses (for details, see Table 1)<sup>14,15</sup>. Only after completing this programme nurses were allowed to conduct the intervention. An additional training programme and annual focused training days were organised during the years of the study.

Eligible women had a histological diagnosis of cervical, vaginal or endometrial cancer; received primary or postoperative external beam radiotherapy with or without concurrent chemotherapy and brachytherapy, or postoperative radiotherapy alone; were 18 years or older, and intended to retain sexual activity. Both single and partnered women, regardless of their sexual orientation, could participate. Exclusion criteria were unavailability for follow-up; insufficient Dutch language proficiency; major affective, psychotic or substance abuse disorder, or posttraumatic stress disorder related to pelvic floor/genital abuse.

The radiation oncologists at the participating centres screened potential participants. Eligible women were informed about the background, rationale and specifics of the study protocol. All participating women provided written informed consent and completed a baseline questionnaire before completion of radiotherapy. In this baseline questionnaire they retrospectively completed questions about sexual functioning and distress prior to cancer symptoms and diagnosis.

The protocol was approved by the Scientific Review Board of the Dutch Cancer Society, by the Medical Ethics Committee Leiden-Den Haag-Delft (number NL62767.058.17), and by the Institutional Review Boards and/or Ethics Committees of the participating centres.

### Randomisation and masking

Participants were assigned unique study identifiers by the local data manager for use in all questionnaires and data files. Participants were randomly assigned (1:1) to the nurse-led rehabilitation intervention or care-as-usual, using block stratified

randomisation (block sizes of 2 and 4). Stratification was based on radiotherapy type (brachytherapy yes/no) and partner status (yes/no). Participants were registered by the local data manager through a secured web-based system, and randomised after completing baseline measurements. Participants, physicians, nurses, and investigators were not masked to treatment allocation.

### Procedures

In the intervention group, all women were counselled and followed by the specifically trained nurse<sup>14</sup>. The content of this nurse-led sexual rehabilitation intervention has been described in detail elsewhere<sup>15</sup> and is summarized in Table 1 and Figure 1. In short, the intervention comprised four one-hour face-to-face sessions at 1, 3, 6, and 12 months post-radiotherapy, synchronized with visits to the radiation oncologist, with an extra session at 2 months for women who received brachytherapy. All nurse-led intervention sessions were audio-taped for checks of adherence to the protocol and assessment of competence by an independent panel. The aim was to conduct random checks of 15% of the sessions, which is customary in this type of research, where a minimum of 10% is considered acceptable within large cohorts<sup>16</sup>.

Both the intervention and care-as-usual groups had a first follow-up session 4-5 weeks after completion of radiotherapy with their radiation oncologist, to evaluate recovery, tumour regression and vaginal healing, and to assess symptoms. All women received a specially developed information booklet which was based on the pilot study<sup>14</sup>. Those who had received radiotherapy with brachytherapy also received a vaginal dilator set (Amielle Comfort®; Owen Mumford) and two tubes of lubrication gel (K-Y Jelly; Johnson & Johnson) free of charge. They were advised to start vaginal dilation for 1 to 3 minutes, 2 to 3 times a week, provided the vagina was sufficiently healed, and to continue regular vaginal dilation throughout the first year after radiotherapy. If sexual intercourse was resumed, this was also considered as part of vaginal dilation, which could be complemented with the use of the dilator set. Women with cervical or vaginal cancers who were under 50 years of age were recommended to receive hormone replacement therapy until the age of about 50.

Prior to the study, the study team at the centres had been queried about their standard protocols regarding sexual rehabilitation within their centre ('care-as-usual'). In most of the centres (90%), specific counselling on sexual rehabilitation and dilation was already a standard topic of information after treatment and during follow-up appointments with their physician. Although the guidance offered to the care-as-usual group could not be completely standardized due to these local practices, it did not involve the structured, tailored nurse-led sexual rehabilitation intervention during follow-up.


**Table 1** Description of the sexual rehabilitation programme

<b>General Features</b>	
<b>Nurses</b>	<ul style="list-style-type: none"> <li>• Each participating centre sent at least two designated oncology nurses; or brachytherapy technicians (two centres); or radiotherapy medical assistants (one centre). In total, 25 oncology nurses were involved in the study, divided over 10 Dutch oncology centres.</li> <li>• The training programme was developed during the pilot study by one clinical psychologist, and two healthcare psychologists, all with at least 25 years expertise in sexuality, conceptualization, methods and skills<sup>14</sup>.</li> <li>• Prior to the start of the trial, all nurses completed a 50-hour study-specific training in the basic principles of sexuality, motivational interviewing, simple cognitive behavioural interventions, and the treatment protocol itself. Because of changes in employment the training was repeated in 2020 for new nurses from some participating centres and for an additional participating centre.</li> <li>• The nurses were supervised by experienced sexologists (N = 12), who were also trained in the treatment protocol.</li> <li>• Over a period of approximately 4 years, the nurses attended six additional training days that focused on a specific theme that was relevant for the study (i.e., vaginal stenosis and dilator use; emotional reactions after loss of participants due to cancer recurrence; the partner relationship; implementation of the intervention). During five of these training days, the supervisors were also present. One of these training days took place online due to the COVID-19 pandemic.</li> </ul>
<b>Structure of the sexual rehabilitation programme (see also figure 1)</b>	<ul style="list-style-type: none"> <li>• The intervention consisted of four one-hour face to face sessions at 1, 3, 6, and 12-months after radiotherapy.</li> <li>• An additional session was scheduled at 2-months after radiotherapy for women who received external beam radiotherapy combined with brachytherapy, during which potential barriers and problems with dilator use were discussed.</li> <li>• An extra follow-up session/telephone consultation of 30 minutes was scheduled between 6 and 12-months post-treatment, if preferred by the participant.</li> <li>• The sexual rehabilitation intervention consisted of 11 modules (see also description of modules below). The modules included topics such as education regarding the specific cancer diagnosis, treatment and importance of long-term regular dilator use, discussing potential experienced barriers to dilator or lubricant use, fear of penetration with dilators and resuming sexual activity, promoting couples' mutual coping and support processes and addressing sexual, body image and relationship concerns. If sexual problems appeared to beyond the scope of the modules, referral options to a psychologist-sexologist were given.</li> <li>• The content of the intervention was personalized for each individual person and was tailored to the participant-specific psychological, relational and somatic factors. During each session, the nurse selected the specific module(s) that fitted the woman's (and her partner's) needs best. See Suvaal et al<sup>15</sup> (chapter 3) for the decision tree for module selection.</li> <li>• The sessions were designed to be face-to-face; however, during the COVID-19 pandemic, sessions could also take place by telephone or video.</li> </ul>
<b>Involvement of the partner</b>	<ul style="list-style-type: none"> <li>• Partners were invited and encouraged to accompany the sessions. Their presence was however not obligatory.</li> </ul>
<b>Costs of the sexual rehabilitation programme</b>	<ul style="list-style-type: none"> <li>• The sexual rehabilitation programme was provided at no cost to the women.</li> </ul>

Table 1 Continued

Description of modules
Module 1: Brief sexual history
This module describes how the nurse can question the patient in-depth about sexual problems on various domains of sexual functioning, including sexual interest/arousal, orgasm, pain and sexual satisfaction. It also covers psycho-education about sexuality and the sexual response curve and provides information about frequently occurring sexual problems and solutions.
Module 2: Pain during intercourse
This module includes practical guidelines that the nurse can provide regarding pain during intercourse after radiotherapy-, with referrals to module 3, 4, 6 and 7, and explains how to provide psycho-education about the circular model of dyspareunia, which is based on a cognitive behavioural framework.
Module 3: Vaginal dryness and health
This module provides the nurse with instructions on how to give advice with regard to treatment of vaginal dryness, pain or irritation. It also includes information regarding vaginal health, such as the use of vaginal creams, avoidance of scratching in response to irritated skin or avoidance of washing with soap.
Module 4: Alternatives for intercourse
The exercise in this module helps the woman and her partner (if available) to explore and discuss non-penetrative alternatives for sexual intercourse.
Module 5: The partner and possible sexual problems
This module can be consulted by the nurse when partners experience temporary sexual problems, such as erectile dysfunction during intercourse. The module also includes a reference to module 1.
Module 6: Gradual exposure towards sexual intercourse
The aim of the steps in this module, which are based on a cognitive behavioural gradual exposure therapy for Genito-Pelvic/Penetration Disorder, is to learn the woman and her partner how to re-engage in sexual intercourse. The steps include: touching of the vaginal opening with the erect penis without penetration, stepwise vaginal insertion of the erect penis without moving, and vaginal insertion of the erect penis with moving.
Module 7: Pelvic floor exercise
This module includes several pelvic floor relaxation exercises for women who experience tension in the pelvic floor muscles.
Module 8: Difficulties with dilator use at home
This module is suitable for women who experience problems with dilator use and who already practiced under supervision of a nurse (see module 9) or for women who do not want to practice under supervision. This module provides the nurse with instructions on how to give specific advice on how to overcome experienced difficulties, after first exploring the problems during dilator use (e.g. pain/discharge, loss of blood or difficulties with inserting the dilator).
Module 9: Using dilators under supervision at the outpatient clinic
This module focuses on women who experience fear with regard to dilator use or who experience difficulties when using vaginal dilators, due to for example tension of the pelvic floor. The nurse-led session is based on therapist-aided exposure therapy for Genito-Pelvic/Penetration Disorder. The goal is to reduce fear of dilator use by using a stepwise exposure session in which the woman - who performs the vaginal dilation by herself - is facilitated by the nurse. During the session, tips are given with regard to a correct and more comfortable use of the dilators. Furthermore, the nurse helps to evaluate and articulate any unhelpful cognitions about what could (or could not) occur during dilator use. In these instances, the exposure is used as a behavioural experiment, to test the tenability of these cognitions. The module also includes advice on how to handle problems that might occur during practicing at home.
Module 10: Exploring and resolving ambivalence with regard to dilator use
The aim of the exercise in this module is to motivate the woman for dilator use, by acknowledging, exploring and resolving ambivalent feelings towards dilator use by motivational interviewing technique. By exploring pros and cons of both dilator use and no dilator use, the woman can be supported in making an informed choice about dilator use. If she decides to use dilators, problems with dilator use are discussed in more detail and how to overcome them. If a woman decides not to use dilators, tampons covered in petroleum jelly (Vaseline) are recommended and guidelines on how to use these are provided to the woman (see module 11).
Module 11: Petroleum jelly (Vaseline) tampons
This module follows module 10, when a woman decides not to use dilators. The module covers guidelines on how to use tampons covered in petroleum jelly (Vaseline).

Note. N = total number of supervisors involved in the study.



**Figure 1** CONSORT diagram. N = total number of patients invited for the study; n = subgroup of patients; RT = Radiotherapy

\*One patient was initially stratified for external beam radiotherapy combined with brachytherapy, but ultimately received external beam radiotherapy alone. Consequently, her rehabilitation trajectory was according to external beam radiotherapy alone; therefore she was moved to external beam radiotherapy alone.

\*One patient was initially stratified for external beam radiotherapy alone, however she received an additional external beam radiotherapy boost. This led to modification in her rehabilitation trajectory to align external beam radiotherapy combined with brachytherapy; therefore she was moved to external beam radiotherapy combined with brachytherapy.

## Outcomes

The primary outcome was overall sexual functioning, as measured with the Female Sexual Function Index (FSFI)<sup>17</sup>. A total score of  $\leq 26.55$  has been validated as cut-off score for diagnosis of female sexual dysfunction<sup>18</sup>. We added 2 questions to the FSFI to assess the frequency of sexual activity with and without sexual intercourse. Secondary outcomes included sexual distress, as measured by the Female Sexual Distress Scale (FSDS; scores  $\geq 15$  have been signified to establish the presence of sexual distress)<sup>19</sup>, compliance with dilator use (assessed using a 4-item questionnaire regarding frequency, duration, sexual intercourse and other vaginal penetration activities), vaginal functioning problems such as shortness, dryness and pain during intercourse (measured by the Cervical Cancer Module of the European Organization for Research and Treatment of Cancer (QLQ-CX24)<sup>20</sup>), and physician-reported vaginal dryness, shortening and/or tightening, and dyspareunia (assessed by standardized clinical examination using the Common Terminology Criteria for Adverse Events (CTCAE, version 4.03)). See supplementary table S2 for additional specific patient and physician-reported outcome measures, with cut-off scores if applicable.

Outcomes were assessed before radiotherapy (retrospective baseline) and 1, 3, 6 and 12-months after radiotherapy. To minimize respondent burden, the baseline questionnaire included only the FSFI and the FSDS. Adverse events related to dilator use were documented. Cancer treatment related adverse events were not considered study-related.

## Statistical analysis

An effect size of  $d=0.50$  indicates a moderate and clinically relevant effect size<sup>21</sup>. This corresponds with a difference of 3.4 points on the primary outcome measure (FSFI), with a standard deviation of 6.8. To achieve 80% power at a 0.05 significance level, each study group required a minimum of 64 evaluable women at 12-months. Considering the 40% dropout rate observed in the pilot study<sup>14</sup>, at least 107 women in both the intervention and care-as-usual group were required, stratified by radiotherapy type and partner status.

During participant recruitment, it became evident that women undergoing both external beam radiotherapy and brachytherapy were more likely to participate, probably due to more advanced age and milder side effects in those receiving pelvic radiotherapy alone. Consequently, the study population comprised relatively young women with cervical carcinoma primarily treated with external beam radiotherapy, concurrent cisplatin-based chemotherapy, and image-guided adaptive brachytherapy. Given the intervention's relevance to these younger women with intensive treatment for cervical

and vaginal carcinomas, we decided to continue enrolment of eligible women regardless of radiotherapy type to a total of 220 women. The study was amended accordingly.

Analyses were based on intention-to-treat, and were conducted with the Statistical Package for Social scientists (version 29) and the GLMM-adaptive package in R (version 4.2.1)<sup>22</sup>. Questionnaire scores were calculated using published algorithms<sup>17,19,20</sup>. Missing values were replaced by the average score of completed items in the same scale for each individual, when  $\geq 75\%$  of items were completed. When a scale consisted of only two items, 100% of the items had to be completed.

To address differences in changes in the primary and secondary outcome measures between groups (intervention versus care-as-usual) over time we modelled either the mean scores, log expected counts or log-odds (depending on the type of variable) as a function of time, of the intervention group and their interaction. In addition, radiotherapy with or without brachytherapy was added as factor to the model. For the physician-reported variables, when fewer than 15 women scored within CTCAE grade 2 and/or 3 events, these scores were combined into a single category with CTCAE grade 1 ('toxicity'), and then compared to CTCAE grade 0 ('no toxicity'). Differences between groups were evaluated based on a generalized linear mixed effects model, specifically depending on the outcome considered we used mixed effects poisson regression (count measurements) or mixed effects logistic regression (dichotomous outcomes). We used a beta distribution instead of a normal distribution for our continuous outcomes, because of the bounded nature of these outcomes (e.g. the FSFI total score takes values between 2-36<sup>17</sup>). In addition, we used a random effects model (i.e., random intercepts and random slopes) to capture the within-subjects correlation. We further explored if there was considerable between-hospital variability. Regarding missing data, the generalized linear mixed effects models give valid results under the missing at random mechanism. To account for any potential model misspecification robust standard errors were computed. We used the Likelihood Ratio Test to test whether the improvement of the intervention group over time was statistically significantly different from the care-as-usual group. The significance level was set at 0.05.

This study was monitored for trial and data compliance by an independent certified monitor and registered under ClinicalTrials.gov number NCT03611517.

## RESULTS

Between Aug 7, 2018, and Dec 31, 2021, 229 women were enrolled and randomly assigned to the nurse-led sexual rehabilitation intervention (n=112, 49%) or to care-as-usual (n=117, 51%) (see Figure 1). 36 Women (16%) discontinued participation before the 12-month assessment. Drop-out was significantly lower in the intervention group (n=13, 12%) than the care-as-usual group (n=23, 20%) ( $p<0.001$ ). Follow-up and/or questionnaire data of 39 women (17%); were not available at one or more timepoints during the 12-month follow-up period: 12 (11%) in the intervention group; 27 (23%) in the care-as-usual group).

Patient, disease and treatment characteristics were well balanced between the two groups (see Table 2). Most women were treated with primary or postoperative external beam radiotherapy combined with brachytherapy (80 (71%) in the intervention group; 82 (70%) in the care-as-usual group) for cervical cancer (98 (87.5%) for the intervention group; 104 (89%) for the care-as-usual group), and had a partner (88 (79%) for the intervention group; 90 (77%) for the care-as-usual group); with mostly male partners (86 (98%) for the intervention group; 90 (100%) for the care-as usual group). Approximately 70% of the women under the age of 50 with cervical cancer received hormonal replacement therapy during follow-up.

Women in the intervention group had on average 4.4 (SD=1.1) intervention sessions, lasting on average 31 minutes (SD=14.6) per session. Most sessions were face-to-face: 102 (94%), 49 (56%), 80 (77%), 68 (69%), 65 (71%) for 1, 2, 3, 6 and 12-months after radiotherapy, respectively. The participation of partners declined over time: among the 88 women in the intervention group with a partner, 40 partners (45.5%) participated at the 1-month session, 31 (35%) at 3-months, 21 (24%) at 6-months, and 14 (17%) at 12-months after radiotherapy. Twenty partners of the 74 partnered women in each arm in the radiotherapy with brachytherapy group (27%) participated in the 2-month session focusing on dilator use. Random checks of protocol adherence and competence assessment indicated a 90% adherence and competence rate. There were no sexual rehabilitation or dilator use related serious adverse events.

**Table 2** Patient, disease and treatment characteristics

		<b>Intervention group n = 112 (48.9%)</b>	<b>Care as Usual group n = 117 (51.1%)</b>
<b>Patient characteristics</b>			
Age	Median in years ( $\pm$ IQR)	42 (17)	41 (19)
Partner	Yes	88 (78.6%)	90 (76.9%)
	Male	86 (97.7%)	90 (100%)
	Female	2 (2.3%)	0
	No	24 (21.4%)	27 (23.1%)
Highest completed level of education	Primary education	7 (6.3%)	6 (5.1%)
	Secondary education	50 (44.6%)	54 (46.2%)
	Higher education	54 (48.2%)	56 (47.9%)
	Missing	1 (0.9%)	1 (0.9%)
Menopausal status before diagnosis	Premenopausal	75 (67.0%)	75 (64.1%)
	Perimenopausal	10 (8.9%)	3 (2.6%)
	Postmenopausal	23 (20.5%)	33 (28.2%)
	Unknown	4 (3.6%)	6 (5.1%)
Vaginal delivery	Yes	68 (60.7%)	69 (59.0%)
	No	40 (35.7%)	43 (36.8%)
	Unknown	2 (1.8%)	5 (4.3%)
	Missing	2 (1.8%)	0
Body Mass Index	Underweight (<18.5)	5 (4.5%)	5 (4.3%)
	Healthy weight (18.5-24.9)	59 (52.7%)	44 (37.6%)
	Overweight (25-29.9)	20 (17.9%)	40 (34.2%)
	Obese ( $>$ 30)	27 (24.1%)	25 (21.4%)
	Missing	1 (0.9%)	3 (2.6%)
Current smoker	Yes	18 (16.1%)	14 (12.0%)
	No	94 (83.9%)	102 (87.2%)
	Unknown	0	1 (0.9%)
World Health Organization performance score	0	85 (75.9%)	89 (76.1%)
	1	24 (21.4%)	25 (21.4%)
	2	2 (1.8%)	3 (2.6%)
	Unknown	1 (0.9%)	0
<b>Disease characteristics</b>			
Type of carcinoma	Cervical carcinoma	98 (87.5%)	104 (88.9%)
	Endometrial carcinoma	7 (6.3%)	8 (6.8%)
	Vaginal carcinoma	7 (6.3%)	5 (4.3%)
Histological type	Cervical		
	• Squamous cell	80 (81.6%)	85 (81.7%)
	• Other	18 (18.4%)	19 (18.3%)
	Endometrium		
	• Endometrioid carcinoma	5 (71.4%)	5 (62.5%)
	• Serous carcinoma	0	1 (12.5%)
	• Mixed or other	2 (28.6%)	2 (25.0%)
	Vagina		
	• Squamous cell	6 (85.7%)	4 (80.0%)
	• Other	1 (14.3%)	1 (20.0%)

Table 2 Continued

		Intervention group n = 112 (48.9%)	Care as Usual group n = 117 (51.1%)
FIGO stage (2009)	Cervical		
	• IB	29 (29.6%)	32 (30.8%)
	• IIA/B	52 (53.1%)	56 (53.8%)
	• IIIA/B	11 (11.2%)	11 (10.6%)
	• IVA	1 (1.0%)	1 (1.0%)
	• Not applicable (if recurrence)	5 (5.1%)	4 (3.8%)
	Endometrium		
	• IA/B	3 (42.9%)	2 (25.0%)
	• II	1 (14.3%)	3 (37.5%)
	• IIIA-C	3 (42.9%)	3 (37.5%)
	Vagina		
• I	4 (51.7%)	2 (40.0%)	
• II	3 (42.9%)	1 (20.0%)	
• III	0	0	
• IVA	0	2 (40.0%)	
Lymph node metastases	Yes	59 (52.7%)	68 (58.1%)
	No	53 (47.3%)	49 (41.9%)
<b>Treatment characteristics</b>			
Treatment centre	Amsterdam Medical Center	16 (14.3%)	15 (12.8%)
	Catharina hospital	13 (11.6%)	12 (10.3%)
	Erasmus Medical Center	24 (21.4%)	26 (22.2%)
	Leiden University Medical Center	23 (20.5%)	22 (18.8%)
	Maastrou	6 (5.4%)	10 (8.5%)
	Netherlands Cancer Institute	3 (2.7%)	2 (1.7%)
	Radboud University Medical Center	11 (9.8%)	13 (11.1%)
	Radiotherapiegroep	2 (1.8%)	3 (2.6%)
	University Medical Center Groningen	5 (4.5%)	4 (3.4%)
	University Medical Center Utrecht	9 (8.0%)	10 (8.5%)
Chemotherapy (concurrent)	Yes	90 (80.4%)	87 (74.4%)
	No	22 (19.6%)	30 (25.6%)
Hyperthermia <sup>#</sup>	Yes	4 (3.8%)	15 (13.8%)
	No	101 (96.2%)	94 (86.2%)
Type of Radiotherapy	Primary EBRT+BT	80 (71.4%)	82 (70.1%)
	Postoperative EBRT+BT	16 (14.3%)	15 (12.8%)
	External Beam Radiotherapy only	14 (12.5%)*	19 (16.2%)
	EBRT with EBRT boost	2 (1.8%)*	1 (0.9%)
Target area External Beam Radiotherapy	Pelvic region	84 (75.0%)	89 (76.1%)
	Pelvic and para-aortal regions	22 (19.6%)	22 (18.8%)
	Pelvic and inguinal regions	6 (5.4%)	4 (3.4%)
	Pelvic, para-aortal, and inguinal regions	0	2 (1.7%)
External Beam Radiotherapy total dose	Median dose in Gy (±IQR)	45 (0)	45 (0)
Brachytherapy	Yes	96 (85.7%)	97 (82.9%)
	No	16 (14.3%)	20 (17.1%)

**Table 2** *Continued*

		<b>Intervention group n = 112 (48.9%)</b>	<b>Care as Usual group n = 117 (51.1%)</b>
Target area Brachytherapy	Intrauterine/vaginal Brachytherapy primary	80 (83.3%)	87 (89.7%)
	Vaginal vault boost postoperative	9 (9.4%)	8 (8.2%)
	Vaginal intracavitary and interstitial (primary or recurrence)	6 (6.3%)	2 (2.1%)
	Vaginal intracavitary primary	1 (1.0)	0


*Note.* EBRT+BT = External Beam Radiotherapy combined with Brachytherapy; FIGO = Fédération Internationale de Gynécologie et d'Obstétrique; IQR = interquartile range; N = total sample; n = subgroup sample.

# = Only applicable for cervical and vaginal carcinoma.

\* = One participant was stratified as EBRT+BT radiotherapy, however she was treated with EBRT only. Her rehabilitation trajectory was according to EBRT alone; therefore she was moved to EBRT alone.

\* = One participant was stratified as EBRT alone, however she received an additional EBRT boost. Her rehabilitation trajectory was according to EBRT+BT; therefore she was moved to EBRT+BT.


Regarding the primary outcome FSFI, for both study groups scores were clearly decreased after radiotherapy (compared to the retrospective baseline scores), whereafter they increased over time. At 12-months FSFI total-scores were 22.57 in the intervention group versus 21.76 in the care-as-usual group, see Figure 2I-II. As the FSFI is very sensitive to sexual activity, we also show the mean scores of sexually active women (with or without intercourse) and women not sexually active. At 12-months, 67 (71%) women in the intervention group and 60 (69%) women in the care-as-usual group were sexually active, with 65 (69%) women in the intervention group and 56 (64%) women in the care-as-usual group reporting sexual intercourse (see supplementary table S3). As shown in Figure 2I-II, FSFI scores for women not sexually active were lower than for sexually active women, while the pattern of decrease and increase over time was similar in both groups.




**Figure 2** Patient-reported average scores on sexual functioning and sexual distress. BM = baseline measurement; CAU = Care As Usual group; FSDS = Female Sexual Distress Scale (higher score is more sexual distress); FSFI = Female Sexual Function Index (higher score is better sexual functioning); INT = Intervention group; M = months; N = observed number of women at the specific timepoint.

Regarding our secondary outcomes, compared to the situation prior to diagnosis, sexual distress as measured by the FSDDS was strongly increased after radiotherapy, whereafter it remained elevated over time (see Figure 2-III). Almost half of the women reported sexual distress to a clinical degree at 12-months after radiotherapy in both study groups (42 (45%) women in the intervention group versus 40 (46%) women in the care-as-usual group, see supplementary table S6).

Figure 3 I-III shows that the majority of the women in both groups had no physician-reported vaginal stenosis, dryness, and dyspareunia during follow-up, followed by grade 1 (not interfering with sexual functioning). Grade 1 vaginal stenosis was seen in 8 (7.5%, intervention group) and 4 (3%, care-as-usual group) women at baseline (before radiotherapy), gradually increasing to 21 (24%) women in the intervention group and 20 (23%) women in the care-as-usual group at 12-months after radiotherapy. Grade 1 vaginal dryness was reported in 2 (2%, intervention group) and 4 (4%, care-as-usual group) women before radiotherapy, increasing to 18 (21%) and 26 (32%) women, respectively, at 12-months after radiotherapy. Grade 1 dyspareunia was assessed in 3 (4%, intervention group) and 10 (12%, care-as-usual group) women before radiotherapy, increasing to 24 (29%) and 14 (20%) women, respectively, at 12-months after radiotherapy. There was no clear increase or decrease in patient-reported feelings of vaginal shortness, dryness and pain during intercourse in the follow-up period (Figure 3 IV-VI), with most sexually active women reporting 'none' or 'a little' (respectively 61 (87%), 55 (78.5%), and 64 (91.5%) in the intervention group and 54 (87%), 54 (87%), and 58 (93.5%) in the care-as-usual group at 12-months after radiotherapy). At 12-months, more substantial ('quite a bit' or 'very much') feelings of vaginal shortness, dryness and pain during intercourse were reported by 9 (13%), 15 (21%), and 6 (9%) sexually active women in the intervention group versus 8 (13%), 8 (13%), and 4 (6.5%) sexually active women in the care-as-usual group, respectively. See supplementary figures S4 and S5 for additional physician and patient-reported outcomes on vaginal functioning.



**Figure 3** Physician-reported clinical measurements and patient-reported vaginal functioning problems (of sexually active women in the past four weeks) on single item level over time. The proportion of women is shown in percentages. BM = baseline measurement; CTCAE = Common Terminology Criteria for Adverse Events; EORTC QLQ-CX24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gynaecological Cancer Module; M = months; N = number of women at risk at the specific timepoint; n = number of sexually active women at risk at the specific timepoint according to EORTC QLQ-CX24 item 19; O = observed number of women at the specific timepoint.



**Figure 4** Patient-reported dilation in the past four weeks over time. The proportion of women is shown in percentages. M = months; mo = month, N = number of women at risk who received dilators; O = observed number of women at the specific timepoint; wk = week.

Figure 4 shows the patient-reported dilation by arm for women in the external beam radiotherapy combined with brachytherapy group. Any type of dilation used at least two times per week, including dilators, vibrators, dildos, fingers or intercourse combined, that was employed by women who received brachytherapy, was reported by 66 (69.5%) women in the intervention group and 60 (64.5%) women in the care-as-usual group at 1-month after radiotherapy, increasing to 90 (97%) women and 82 (90%) women at 3-months after radiotherapy, respectively (Figure 4-IV). Any type of dilation  $\geq 2$  times per week slightly decreased to 70 (85%) women in the intervention group, and 57 (75%) women in the care-as-usual group at 12-months after radiotherapy.

Likelihood ratio tests indicated no significant improvement in model fit when including the treatment group ( $p > 0.05$ ). No differences in FSFI total scores were found between the groups at any timepoint ( $p = 0.37$ ). This suggests that the sexual rehabilitation intervention had no significant impact on better sexual functioning compared to the care-as-usual group. This result applied to most (95%) of the other outcomes (for more details, see supplementary table S3).

## DISCUSSION

The SPARC trial is to our knowledge the first robustly powered randomised trial to investigate the efficacy of a nurse-led sexual rehabilitation intervention to improve sexual recovery and compliance with dilator use for women treated with radiotherapy and brachytherapy for gynaecological cancers. Contrary to expectations based on the pilot study<sup>14</sup>, this trial did not show a significant benefit of the nurse-led sexual rehabilitation intervention over care-as-usual in improving sexual functioning, dilator compliance, and reducing sexual distress and vaginal symptoms, one year after radiotherapy. However, compared to previous data on similar treatments, women in both study groups had relatively high rates of sexual activity, with overall 70% reporting to be sexually active at 12-months, compared to 40-50% in previous studies<sup>1,2,4</sup>. Most women in both study groups had no or little physician-reported vaginal stenosis, with most sexually active women reporting no or only a little feeling of vaginal shortness, dryness and pain during intercourse at 12-months after radiotherapy. Substantial vaginal and sexual functioning problems were rare. Also, any dilation  $\geq 2$  times weekly, including dilators, vibrators, dildos, fingers or intercourse combined, was reported by 85% of the participants in the intervention group and by 75% of the participants in the care-as-usual group at 12-months, similar to the pilot study<sup>14</sup>. Almost half of the women in both groups continued to experience clinical-level sexual distress even at the 12-month post-radiotherapy follow-up, indicating the complexity of sexual functioning.

The lack of notable differences in outcomes between the two groups is likely explained by the fact that both healthcare professionals in gynaecological oncology and patient advocacy groups have become more aware of the importance of early sexual rehabilitation care and associated issues since the start of the trial. Since the completion of the pilot study<sup>14</sup>, standard sexual rehabilitation care in the Netherlands already involved a one-month post-radiotherapy appointment with a physician or nurse. During this appointment, women received comprehensive verbal and written information on sexual rehabilitation. Additionally, a vaginal dilator set with lubrication gel was provided free of charge to women who had undergone pelvic radiotherapy with brachytherapy, along with explicit guidance on use, both within and outside of trial participation. The comprehensive training of the nurses conducting the intervention in the SPARC trial led to further in-depth knowledge, and to increased skills in informing and coaching and addressing specific personal issues and questions for these women across all centres, including in most centres those randomised to the care-as-usual group. In addition, during the study, the Dutch patient advocacy group for women with gynaecological cancers (Olijf) developed a specialized patient website focused on sexual rehabilitation<sup>23</sup>. The website's widespread visibility and accessible information on sexuality and post-treatment rehabilitation were shared with all trial participants, fostering informal discussions among patients in online forums and with caregivers, both at the treatment centres and beyond.

To gain a more comprehensive understanding of the coaching and information of the women randomised to the care-as-usual group, we incorporated post-hoc questionnaires for the centres about their standard care. The responses revealed that six out of ten centres had implemented additional improvements to standard sexual rehabilitation care during the study period, and that half of the centres had arranged at least one additional care pathway appointment within the first year after radiotherapy, with a specific focus on sexuality. Moreover, all centres ensured that sexuality remained a standard topic in all follow-up appointments with physicians. As the sexual rehabilitation sessions with the nurse were directly scheduled after these appointments, sexuality was discussed at the same timepoints in both study groups.

Women with cervical cancer constituted the large majority (88%) of the current study population, making our study outcomes particularly relevant for these relatively young women treated with intensive combined chemoradiotherapy and brachytherapy. The trial's guidelines on sexual rehabilitation align with recent guidelines that advocate for heightened attention to post-radiotherapy sexual functioning in gynaecological cancer patients, including those treated with pelvic radiotherapy alone, albeit with more emphasis on rehabilitation after treatment in general and less on vaginal dilation<sup>24,25</sup>. Considering that nurses can devote more time to patient interaction, are often easily

accessible for patients, and can integrate their role in information and counselling in other clinical tasks, their role would be a cost-effective strategy for dedicated sexual rehabilitation. The cost-effectiveness of the nurse-led intervention versus care-as-usual is topic of subsequent analysis.

This trial has several notable strengths, including the well-powered randomised trial design, the participation of all Dutch gynaecological oncology centres, a limited drop-out of study participants, the use of a clear treatment protocol and extensive training protocol, including an adherence and competency assessment by an independent panel, and the invitation to the women's partners to join the intervention sessions. This study also has some limitations. First, as it turned out, the improvements in standard sexual rehabilitation after completion of radiation therapy may have unintentionally impacted on care of the care-as-usual group. Despite instructions to physicians and nurses to manage both study groups differently, their involvement with both study groups may have resulted similar initial post-radiotherapy psychosexual care. This well-known problem of contamination within individually randomized intervention studies could have been avoided by cluster randomization (i.e., on centre level instead of patient level). However, this method also introduces other potential threats to internal validity, as the number of centres in our study is limited and only a part of the centres could be randomized (n = 8, as a consequence of the training that was already completed in two centres for the pilot study)<sup>14</sup>. Because of the specific variation in the patient population, radiotherapy treatment procedures and follow-up procedures across centres, we decided to randomize on patient level. Furthermore, the FSFI which is widely employed to evaluate sexual functioning in female cancer survivors, could yield biased results for sexually inactive women due to lack of a partner, relationship quality, or reasons unrelated to cancer treatment effects<sup>17,26</sup>. To mitigate this, we randomised participants with stratification based on partner status, and included the response option 'not applicable, no partner' for items concerning the partner relationship, thereby minimising potential imbalance in the study outcomes. It is also possible that sexual functioning may further improve on the longer term. To investigate potential further recovery and to assess if the high rates of sexual activity will be sustained over time, a long-term evaluation at 24 months after radiotherapy was added per protocol amendment and results will be available next year. Finally, it could be argued that this study attracted relatively young and motivated participants, and that the improvement in vaginal and sexual functioning in both study groups was due to recovery over time. However, prospective studies involving cohorts of women treated with radio(chemo)therapy and brachytherapy for advanced or recurrent cervical cancer, without any standard sexual rehabilitation care, reported clearly higher prevalence rates of feelings of vaginal shortness, dryness and pain during sexual activity, vaginal stenosis and lower compliance with dilator use<sup>4,7,8,27,28</sup>.

The prospective EMBRACE vaginal morbidity substudy, which did recommend sexual rehabilitation counselling after treatment, along with clear instructions on dilator use, demonstrated similar outcomes to our study regarding stenosis (physician-reported), vaginal shortness, dryness, and dyspareunia (patient-reported)<sup>29</sup>. Half of sexually active women reported feelings of vaginal shortness, dryness, and intercourse-related pain, which was also the case in our study cohort, although in vast majority rated as 'a little'. However, in the EMBRACE vaginal morbidity substudy cohort 54% reported to be sexually active at 12 months, while this was approximately 70% in the SPARC trial, possibly reflecting the effects of the increased patient education and awareness on early sexual rehabilitation. Regarding vaginal stenosis, either no or only mild stenosis was found at 12 months in both study cohorts, probably resulting from the improved radiotherapy and brachytherapy techniques causing less severe vaginal effects than in historical cohorts<sup>30</sup> along with more frequent vaginal dilation reported by the participants. In the SPARC trial, 85% (intervention) versus 75% (care-as-usual) of women who received brachytherapy, reported using any form of dilation at least twice a week at 12 months, indicating high compliance.

The results of the SPARC trial highlight the improved sexual rehabilitation care for women undergoing intensive radio(chemo)therapy and brachytherapy in the Netherlands, both before and during the study period, emphasizing the importance of awareness, education, and comprehensive care. This may have resulted in comparable sexual rehabilitation for both study groups. We therefore regard this care-as-usual approach as best practice to improve sexuality and thus quality-of-life after gynaecological cancer treatment. This approach encompasses thorough patient information, as well as a sexual rehabilitation appointment with a specifically trained dedicated nurse at one-month post-radiotherapy, including explicit guidance on dilator use and coaching on resuming sexual activities for women who underwent radiotherapy combined with brachytherapy, and dedicated follow-up regarding sexual functioning and dilator use over the first year after completion of treatment.

## SUPPLEMENTARY MATERIAL

**Table S1** Participating centres including study teams

Centre	Principle Investigator (and Associated Investigators)	Nurses	Supervisors
Amsterdam Medical Center	Henrike Westerveld	Wilma van der Ham-Paalman Sandra Diergaarde Wendy Lesterhuis	Ellen Laan† Hanneke Termeer
Catharina Hospital	Jeltsje Cnossen Hetty van den Berg	Noor Vincent Ivonne Oomen	Rian Brus Simone Speelman
Erasmus Medical Center	Jan Willem Mens Helena van Doorn Remi Nout	Claudia Mangelaars Karin Dupree Nicoline Schuur – van 't Hof Sabine Blom Christel de Jager-Blom	Hanneke Bolt
Leiden University Medical Center	Carien Creutzberg Cor de Kroon Laura Velema	Corine de Jong Mirjam Laman	Charlotte Tuijnman- Raasveld Ellen de Groot
Maastrou	Ludy Lutgens	Moniek Kamps Charlotte Penders	Reinhilde Melles
Netherlands Cancer Institute	Marlies Nowee	Kirsten de Greef Erin Gardebroek-de Boer	Ilaniek Zantingh
Radboud University Medical Center	An Snyers	Annemieke Janssens Lotte Knapen	Marianne Vergeer
Radiotherapiegroep	Dorien Haverkort	Janine de Neeff Truus Kroeze	Irma Bosman
University Medical Center Groningen	Jannet Beukema	Bianca Kramer-Medema Nina van Linde	Ria Bosgraaf
University Medical Center Utrecht	Ina Jurgenliemk-Schulz	Nicole van den Berg Catharina van der Linden-Hunziker Ankie Krol Veraar	Ilaniek Zantingh

**Table S2** Additional patient and physician-reported outcomes

<b>Variable</b>	<b>Questionnaire</b>	<b>Clinical cut-off score</b>
Sexual functioning	FSFI	≤26.55
Sexual desire	FSFI	NA
Sexual arousal	FSFI	NA
Vaginal lubrication	FSFI	NA
Orgasmic function	FSFI	NA
Sexual satisfaction	FSFI	NA
Sexual pain	FSFI	NA
Sexual distress	FSDS	≥15
Symptom experience	EORTC QLQ-CX24	NA
Body image	EORTC QLQ-CX24/QLQ-EN24	NA
Sexual/vaginal functioning (dryness, shortness, tightness, pain during intercourse)	EORTC QLQ-CX24/QLQ-EN24	NA
Vaginal tightness	EORTC QLQ-CX24/QLQ-EN24	NA
Lymphedema	EORTC QLQ-CX24/QLQ-EN24	NA
Peripheral neuropathy	EORTC QLQ-CX24	NA
Menopausal symptoms	EORTC QLQ-CX24	NA
Sexual worry	EORTC QLQ-CX24	NA
Sexual activity	EORTC QLQ-CX24/QLQ-EN24	NA
Sexual enjoyment	EORTC QLQ-CX24/QLQ-EN24	NA
Urological symptoms	EORTC QLQ-EN24	NA
Gastrointestinal symptoms	EORTC QLQ-EN24/QLQ-EN24	NA
Sexual interest	EORTC QLQ-EN24	NA
Fear of non-penetration sexual activity	FSQ	NA
Fear of coitus/vaginal penetration	FSQ	NA
Relationship dissatisfaction	MMQ	≥20
Psychological distress	HADS	≥14
Depression	HADS	≥7
Anxiety	HADS	≥7
Physical function	EORTC QLQ-C30	NA
Role function	EORTC QLQ-C30	NA
Emotional function	EORTC QLQ-C30	NA
Cognitive function	EORTC QLQ-C30	NA
Social function	EORTC QLQ-C30	NA
Fatigue	EORTC QLQ-C30	NA
Nausea/vomiting	EORTC QLQ-C30	NA
Pain	EORTC QLQ-C30	NA
Dyspnoea	EORTC QLQ-C30	NA

**Table S2** *Continued*

<b>Variable</b>	<b>Questionnaire</b>	<b>Clinical cut-off score</b>
Sleep disturbance	EORTC QLQ-C30	NA
Appetite loss	EORTC QLQ-C30	NA
Constipation	EORTC QLQ-C30	NA
Diarrhoea	EORTC QLQ-C30	NA
Financial impact	EORTC QLQ-C30	NA
Global QoL	EORTC QLQ-C30	NA
Treatment related stress – intrusion	IES	NA
Treatment related stress – avoidance	IES	NA
Cost-effectiveness		
Sexual health care use	-	NA
Quality of life	EQ-5D-5L	NA
Credibility of analogue therapy rationales	CEQ	NA
Physician-reported Bleeding	CTCAE	≥grade 3 = severe
Physician-reported Mucositis	CTCAE	≥grade 3 = severe
Physician-reported Discharge	CTCAE	≥grade 3 = severe
Physician-reported Fibrosis	CTCAE	≥grade 3 = severe
Physician-reported Atrophy/telangiectasia	CTCAE	≥grade 3 = severe
Physician-reported Pain	CTCAE	≥grade 3 = severe
Physician-reported Dyspareunia	CTCAE	≥grade 3 = severe
Physician-reported vaginal estradiol/estriol	CRF	NA
Physician-reported hormone replacement therapy	CRF	NA

*Note.* CEQ = Credibility/Expectancy Questionnaire; CRF = Case Report Form; CTCAE = Common Terminology Criteria for Adverse Events; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gynaecological Cancer Module; EORTC QLQ-EN24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module; EQ-5D-5L = EuroQol 5D-5L; FSDS = Female Sexual Distress Scale; FSFI = Female Sexual Function Index; FSQ = Fear of Sexuality Questionnaire; HADS = Hospital Anxiety and Depression Scale; IES = Impact of Event Scale; MMQ = Maudsley Marital Questionnaire; NA = not applicable

**Table S3** Total and subscale mean values at retrospective baseline (for FSFI and FSDS) 1, 3, 6 and 12 months after radiotherapy and GLMM likelihood ratio test outcomes of primary and secondary continuous outcome measures

Outcome measure (range score)	Assessment												GLMM outcomes						
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)			
	N	SD	%	N	SD	%	N	SD	%	N	SD	%	N	M/			SD		
<b>Primary</b>																			
Sexual functioning																			
FSFI total (2-36)																			
Intervention	112	28.08	6.48	108	18.36	10.27	106	10.27	106	21.98	9.45	98	23.82	8.83	94	22.57	9.30	10.88(10)	0.37
Care-as-usual	117	28.30	7.07	110	17.38	10.64	106	10.64	106	22.26	9.10	98	22.89	8.74	87	21.76	10.42		
Sexual desire																			
FSFI sexual desire (1.2-6)																			
Intervention	112	3.81	0.99	108	2.92	1.25	106	1.25	106	3.05	1.27	99	3.31	1.30	94	2.99	1.32	7.59(10)	0.67
Care-as-usual	117	3.76	0.99	110	2.80	1.24	106	1.24	106	2.99	1.23	98	3.04	1.18	88	3.08	1.34		
Sexual arousal																			
FSFI arousal (0-6)																			
Intervention	112	4.75	1.40	108	2.93	2.09	106	2.09	106	3.63	1.95	98	3.90	1.89	94	3.52	1.98	13.16(10)	0.21
Care-as-usual	117	4.81	1.35	110	2.72	2.31	106	2.31	106	3.67	1.90	98	3.75	1.91	88	3.69	2.07		
Vaginal lubrication																			
FSFI lubrication (0-6)																			
Intervention	112	5.14	1.49	108	3.10	2.43	106	2.43	106	3.76	2.19	98	4.15	2.11	94	3.88	2.23	4.06(10)	0.95
Care-as-usual	117	5.24	1.52	110	2.89	2.52	106	2.52	106	3.93	2.14	98	4.17	2.13	88	3.80	2.40		
Orgasmic function																			
FSFI orgasm (0-6)																			
Intervention	112	4.80	1.32	108	3.15	2.35	106	2.35	106	3.88	2.10	98	4.05	1.91	94	3.95	1.98	6.52(10)	0.77
Care-as-usual	117	4.97	1.54	110	2.98	2.49	106	2.49	106	4.03	2.11	98	4.19	2.11	88	3.84	2.32		
Sexual satisfaction																			
FSFI satisfaction (0-6)																			
Intervention	112	4.88	1.19	108	3.77	1.54	106	1.54	106	4.11	1.59	98	4.40	1.35	94	4.18	1.53	1.49(10)	0.99
Care-as-usual	117	4.77	1.36	110	3.62	1.58	106	1.58	106	4.11	1.52	98	4.20	1.49	87	4.06	1.54		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	M/SD	%	N	M/SD	%	N	M/SD	%	N	M/SD	%	N	M/SD			%
Sexual pain																	
FSFI pain (0-6)																	
Intervention	112	4.70	1.82	108	2.49	2.52	106	3.54	2.28	98	4.02	2.08	94	4.03	2.25	10.75(10)	0.37
Care-as-usual	117	4.75	1.89	110	2.37	2.45	106	3.54	2.28	98	3.54	2.18	87	3.38	2.52		
Sexual activity																	
Intervention	20	18.0	..	45	41.7	..	36	34.0	..	34	34.7	..	27	28.7	..	0.54(5)	0.99
Never	33	29.7	..	26	24.1	..	32	30.2	..	29	29.6	..	36	38.3	..		
Several times per month	20	18.0	..	17	15.7	..	17	16.0	..	16	16.3	..	15	16.0	..		
1 time/week	38	34.2	..	20	18.5	..	21	19.8	..	19	19.4	..	16	17.0	..		
≥2 times/week																	
Care-as-usual	22	19.0	..	45	40.9	..	37	34.9	..	34	34.7	..	27	31.0	..		
Never	37	31.9	..	28	25.5	..	34	32.1	..	37	37.8	..	37	42.5	..		
Several times per month	28	24.1	..	11	10.0	..	16	15.1	..	11	11.2	..	11	12.6	..		
1 time/week	29	25.0	..	26	23.6	..	19	17.9	..	16	16.3	..	12	13.8	..		
≥2 times/week																	
Sexual Intercourse																	
Intervention	15	13.6	..	62	57.9	..	37	34.9	..	25	25.5	..	29	30.9	..	3.36(3)	0.34
Never	33	30.0	..	19	17.8	..	24	22.6	..	28	28.6	..	22	23.4	..		
Several times per month	18	16.4	..	14	13.1	..	22	20.8	..	20	20.4	..	26	27.7	..		
1 time/week	44	40.0	..	12	11.2	..	23	21.7	..	25	25.5	..	17	18.1	..		
≥2 times/week																	
Care-as-usual	20	17.1	..	71	64.5	..	37	34.9	..	37	37.8	..	31	35.6	..		
Never	37	31.6	..	13	11.8	..	32	30.2	..	26	26.5	..	25	28.7	..		
Several times per month	25	21.4	..	7	6.4	..	17	16.0	..	13	13.3	..	13	14.9	..		
1 time/week	35	29.9	..	19	17.3	..	20	18.9	..	22	22.4	..	18	20.7	..		
≥2 times/week																	

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes					
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)		
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %			SD	
<b>Secondary</b>																		
Sexual Distress																		
FSDS (0-48)																		
Intervention	112	9.32	9.40	107	14.37	10.49	106	13.69	10.55	10.55	98	14.17	10.31	94	14.65	12.07	7.57(10)	0.67
Care-as-usual	117	8.74	9.36	110	12.95	10.01	106	13.17	9.92	9.92	98	14.35	11.36	87	13.94	10.97		
Vaginal dilation																		
Dilator use																		
Intervention				43	45.3		8	8.6			14	16.3		22	26.8			
Never				3	3.2		6	6.5			8	9.3		19	23.2			
Several times per month				5	5.3		12	12.9			20	23.3		15	18.3			
1 time/week				10	10.5		27	29.0			16	18.6		17	20.7			
2 times/week				29	30.5		38	40.9			25	29.1		9	11.0			
3 times/week				5	5.3		2	2.2			3	3.5		0	0			
4-6 times/week				0	0		0	0			0	0		0	0			
Daily																		
Care-as-usual																		
Never				40	43.0		17	18.7			23	27.1		29	38.2			
Several times per month				4	4.3		12	13.2			13	15.3		23	30.3			
1 time/week				5	5.4		9	9.9			19	22.4		6	7.9			
2 times/week				16	17.2		21	23.1			15	17.6		10	13.2			
3 times/week				25	26.9		29	31.9			13	15.3		6	7.9			
4-6 times/week				1	1.1		3	3.3			1	1.2		2	2.6			
Daily				2	2.2		0	0			1	1.2		0	0			

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)
	N	SD	%	N	SD	%	N	SD	%	N	SD	%	N	SD	%		
Vaginal dilation Vibrator/dildo/fingers Intervention																1.90(4)	0.75
<i>Never</i>	..	..	..	67	70.5	..	48	51.6	..	46	53.5	..	38	46.3	..		
<i>Several times per month</i>	..	..	..	12	12.6	..	25	26.9	..	21	24.4	..	28	34.1	..		
<i>1 time/week</i>	..	..	..	7	7.4	..	12	12.9	..	11	12.8	..	10	12.2	..		
<i>2 times/week</i>	..	..	..	4	4.2	..	6	6.5	..	6	7.0	..	2	2.4	..		
<i>3 times/week</i>	..	..	..	4	4.2	..	2	2.2	..	2	2.3	..	4	4.9	..		
<i>4-6 times/week</i>	..	..	..	1	1.1	..	0	0	..	0	0	..	0	0	..		
<i>Daily</i>	..	..	..	0	0	..	0	0	..	0	0	..	0	0	..		
Care-as-usual																	
<i>Never</i>	..	..	..	68	73.1	..	58	63.7	..	49	57.6	..	46	60.5	..		
<i>Several times per month</i>	..	..	..	12	12.9	..	21	23.1	..	23	27.1	..	19	25.0	..		
<i>1 time/week</i>	..	..	..	2	2.2	..	6	6.6	..	5	5.9	..	5	6.6	..		
<i>2 times/week</i>	..	..	..	7	7.5	..	2	2.2	..	2	2.4	..	5	6.6	..		
<i>3 times/week</i>	..	..	..	2	2.2	..	2	2.2	..	3	3.5	..	1	1.3	..		
<i>4-6 times/week</i>	..	..	..	1	1.1	..	1	1.1	..	2	2.4	..	0	0	..		
<i>Daily</i>	..	..	..	1	1.1	..	1	1.1	..	1	1.2	..	0	0	..		
Vaginal dilation Intercourse Intervention																2.33(4)	0.68
<i>Never</i>	..	..	..	60	63.2	..	35	37.6	..	22	25.6	..	25	30.5	..		
<i>Several times per month</i>	..	..	..	10	10.5	..	18	19.4	..	24	27.9	..	18	22.0	..		
<i>1 time/week</i>	..	..	..	14	14.7	..	21	22.6	..	16	18.6	..	23	28.0	..		
<i>2 times/week</i>	..	..	..	9	9.5	..	13	14.0	..	16	18.6	..	11	13.4	..		
<i>3 times/week</i>	..	..	..	2	2.1	..	5	5.4	..	6	7.0	..	3	3.7	..		
<i>4-6 times/week</i>	..	..	..	0	0	..	0	0	..	1	1.2	..	2	2.4	..		
<i>Daily</i>	..	..	..	0	0	..	1	1.1	..	1	1.2	..	0	0	..		



Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %			SD
Care-as-usual																	
<i>Never</i>	..	..	..	62	66.7	..	34	37.4	..	32	37.6	..	26	34.2	..		
<i>Several times per month</i>	..	..	..	12	12.9	..	27	29.7	..	28	32.9	..	23	30.3	..		
<i>1 time/week</i>	..	..	..	5	5.4	..	12	13.2	..	9	10.6	..	12	15.8	..		
<i>2 times/week</i>	..	..	..	6	6.5	..	9	9.9	..	10	11.8	..	8	10.5	..		
<i>3 times/week</i>	..	..	..	5	5.4	..	6	6.6	..	4	4.7	..	3	3.9	..		
<i>4-6 times/week</i>	..	..	..	2	2.2	..	2	2.2	..	1	1.2	..	3	3.9	..		
<i>Daily</i>	..	..	..	1	1.1	..	1	1.1	..	1	1.2	..	1	1.3	..		
Any type of vaginal dilation $\geq 2$ times/week																1.39(4)	0.85
Intervention																	
<i>Yes</i>	..	..	..	66	69.5	..	90	96.8	..	81	94.2	..	70	85.4	..		
<i>No</i>	..	..	..	29	30.5	..	3	3.2	..	5	5.8	..	12	14.6	..		
Care-as-usual																	
<i>Yes</i>	..	..	..	60	64.5	..	82	90.1	..	69	81.2	..	57	75.0	..		
<i>No</i>	..	..	..	33	35.5	..	9	9.9	..	16	18.8	..	19	25.0	..		
Sexual functioning EORTC QLQ-CX24 (0-100)																10.64(8)	0.22
Intervention																	
Care-as-usual	..	..	..	52	26.44	19.65	76	22.59	20.18	77	21.43	18.75	70	18.69	19.32		
Vaginal symptoms EORTC QLQ-CX24 (0-100)																	
Intervention	..	..	..	107	16.30	14.90	106	11.43	11.83	98	11.0	12.71	94	10.99	13.19		
Care-as-usual	..	..	..	109	16.00	14.46	106	12.06	13.38	97	10.20	12.39	87	10.47	13.38		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes					
	T1			T2			T3			T4			T5			LRT(df)	P (overall model)	
	N	SD	%	N	SD	%	N	SD	%	N	SD	%	N	SD	%			
Sexual/vaginal functioning EORTC QLQ-CX24																		
Vaginal dryness Intervention																	0.83(8)	0.99
<i>Not at all</i>	..	..	..	20	38.5	..	35	46.1	..	35	45.5	..	36	51.4	..			
<i>A little</i>	..	..	..	25	48.1	..	22	28.9	..	27	35.1	..	19	27.1	..			
<i>Quite a bit</i>	..	..	..	5	9.6	..	11	14.5	..	12	15.6	..	11	15.7	..			
<i>Very much</i>	..	..	..	2	3.8	..	8	10.5	..	3	3.9	..	4	5.7	..			
Care-as-usual																		
<i>Not at all</i>	..	..	..	25	50.0	..	30	42.9	..	26	39.4	..	31	50.0	..			
<i>A little</i>	..	..	..	14	28.0	..	33	47.1	..	31	47.0	..	23	37.1	..			
<i>Quite a bit</i>	..	..	..	9	18.0	..	3	4.3	..	7	10.6	..	4	6.5	..			
<i>Very much</i>	..	..	..	2	4.0	..	4	5.7	..	2	3.0	..	4	6.5	..			
Sexual/vaginal functioning EORTC QLQ-CX24																		
Vaginal shortness Intervention																	1.18(8)	0.99
<i>Not at all</i>	..	..	..	24	46.2	..	41	53.9	..	42	54.5	..	40	57.1	..			
<i>A little</i>	..	..	..	21	40.4	..	22	28.9	..	20	26.0	..	21	30.0	..			
<i>Quite a bit</i>	..	..	..	3	5.8	..	10	13.2	..	11	14.3	..	7	10.0	..			
<i>Very much</i>	..	..	..	4	7.7	..	3	3.9	..	4	5.2	..	2	2.9	..			
Care-as-usual																		
<i>Not at all</i>	..	..	..	23	46.0	..	35	50.0	..	29	43.9	..	34	54.8	..			
<i>A little</i>	..	..	..	21	42.0	..	27	38.6	..	28	42.4	..	20	32.3	..			
<i>Quite a bit</i>	..	..	..	4	8.0	..	8	11.4	..	8	12.1	..	4	6.5	..			
<i>Very much</i>	..	..	..	2	4.0	..	0	0	..	1	1.5	..	4	6.5	..			

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	SD	%	N	SD	%	N	SD	%	N	SD	%	N	SD			%
Sexual/vaginal functioning EORTC QLQ-CX24	..	..	..	22	42.3	..	47	61.8	..	54	70.1	..	51	72.9	..	3.23(8)	0.92
Vaginal tightness Intervention	..	..	..	19	36.5	..	24	31.6	..	14	18.2	..	14	20.0	..		
<i>Not at all</i>	..	..	..	7	13.5	..	5	6.6	..	8	10.4	..	5	7.1	..		
<i>Quite a bit</i>	..	..	..	4	7.7	..	0	0	..	1	1.3	..	0	0	..		
<i>Very much</i>	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..		
Care-as-usual	..	..	..	25	50.0	..	33	47.1	..	38	57.6	..	39	62.9	..		
<i>Not at all</i>	..	..	..	22	44.0	..	28	40.0	..	20	30.3	..	16	25.8	..		
<i>A little</i>	..	..	..	1	2.0	..	7	10.0	..	8	12.1	..	4	6.5	..		
<i>Quite a bit</i>	..	..	..	2	4.0	..	2	2.9	..	0	0	..	3	4.8	..		
<i>Very much</i>	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..		
Sexual/vaginal functioning EORTC QLQ-CX24	..	..	..	18	34.6	..	31	40.8	..	34	44.2	..	37	52.9	..	1.24(8)	0.99
Pain during intercourse Intervention	..	..	..	29	55.8	..	38	50.0	..	35	45.5	..	27	38.6	..		
<i>Not at all</i>	..	..	..	4	7.7	..	6	7.9	..	8	10.4	..	6	8.6	..		
<i>A little</i>	..	..	..	1	1.9	..	1	1.3	..	0	0	..	0	0	..		
<i>Quite a bit</i>	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..		
<i>Very much</i>	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..		
Care-as-usual	..	..	..	18	36.0	..	27	38.6	..	26	39.4	..	37	59.7	..		
<i>Not at all</i>	..	..	..	28	56.0	..	38	54.3	..	35	53.0	..	21	33.9	..		
<i>A little</i>	..	..	..	1	2.0	..	4	5.7	..	5	7.6	..	4	6.5	..		
<i>Quite a bit</i>	..	..	..	3	6.0	..	1	1.4	..	0	0	..	0	0	..		
<i>Very much</i>	..	..	..	..	..	..	..	..	..	..	..	..	..	..	..		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	M/SD	%	N	M/SD	%	N	M/SD	%	N	M/SD	%	N	M/SD			%
Sexual worry EORTC QLQ-CX24 (0-100)	..	..	..	107	39.25	32.96	105	26.98	28.53	98	21.43	27.60	94	22.34	29.89	2.99(8)	0.94
Care-as-usual	..	..	..	109	37.00	32.18	106	25.47	25.43	98	24.15	30.57	87	19.92	28.96		
Sexual activity EORTC QLQ-CX24 (0-100)	..	..	..	107	21.18	24.40	105	33.97	27.34	98	39.80	26.93	94	36.17	26.62	8.89(8)	0.35
Care-as-usual	..	..	..	109	22.94	29.29	106	30.82	27.87	98	30.95	27.18	87	34.87	28.26		
Sexual enjoyment EORTC QLQ-CX24 (0-100)	..	..	..	52	58.97	26.09	76	59.65	29.47	77	62.77	24.76	70	62.38	28.33	11.58(8)	0.17
Care-as-usual	..	..	..	50	60.67	29.11	70	62.38	27.76	66	60.10	23.55	62	63.98	27.86		
Sexual interest EORTC QLQ-EN24 (0-100)	..	..	..	107	30.84	27.36	105	34.92	27.50	98	38.78	27.78	94	34.04	29.32	4.2(8)	0.84
Care-as-usual	..	..	..	109	30.28	25.88	106	34.91	27.36	98	35.71	24.99	87	34.48	28.05		
Symptom experience EORTC QLQ-CX24 (0-100)	..	..	..	107	15.89	10.55	105	13.45	8.82	98	14.13	9.63	94	13.38	10.10	3.01(8)	0.93
Care-as-usual	..	..	..	109	16.51	10.75	106	14.47	11.12	97	13.93	10.04	87	13.27	9.97		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %			SD
Body image EORTC QLQ-CX24 (0-100)	..	..	..	107	31.67	27.59	105	27.41	27.99	98	27.55	27.60	94	29.55	28.25	4.17(8)	0.84
Intervention	..	..	..	109	29.46	26.47	104	28.95	26.02	98	27.89	25.04	87	26.44	24.80		
Care-as-usual	..	..	..	109	29.46	26.47	104	28.95	26.02	98	27.89	25.04	87	26.44	24.80		
Lymphedema EORTC QLQ-CX24 (0-100)	..	..	..	107	11.22	21.45	106	11.32	21.52	98	14.97	26.70	94	13.83	23.14	6.16(8)	0.63
Intervention	..	..	..	109	8.26	19.85	106	11.01	23.33	98	10.88	21.29	87	15.33	27.28		
Care-as-usual	..	..	..	109	8.26	19.85	106	11.01	23.33	98	10.88	21.29	87	15.33	27.28		
Peripheral neuropathy EORTC QLQ-CX24 (0-100)	..	..	..	107	11.84	20.09	106	16.67	26.53	98	15.99	24.51	94	17.02	25.28	2.68(6)	0.85
Intervention	..	..	..	109	10.70	19.71	106	14.78	26.46	98	14.63	25.80	87	15.33	24.80		
Care-as-usual	..	..	..	109	10.70	19.71	106	14.78	26.46	98	14.63	25.80	87	15.33	24.80		
Menopausal symptoms EORTC QLQ-CX24 (0-100)	..	..	..	107	36.76	32.68	106	37.11	32.31	98	32.65	33.15	94	30.85	30.23	4.27(8)	0.83
Intervention	..	..	..	109	31.19	31.84	106	30.82	33.40	98	28.91	30.13	87	23.37	28.36		
Care-as-usual	..	..	..	109	31.19	31.84	106	30.82	33.40	98	28.91	30.13	87	23.37	28.36		
Urological symptoms EORTC QLQ-CX24 (0-100)	..	..	..	107	18.77	18.28	105	13.41	14.36	98	15.14	15.48	94	13.21	12.78	3.32(8)	0.91
Intervention	..	..	..	109	17.74	15.92	106	15.17	16.34	98	15.05	14.88	87	14.56	14.45		
Care-as-usual	..	..	..	109	17.74	15.92	106	15.17	16.34	98	15.05	14.88	87	14.56	14.45		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes P (overall model)				
	T1			T2			T3			T4				T5			
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD		N	M/ %	SD	
Gastrointestinal symptoms EORTC QLQ-CX24 (0-100)	..	..	..	107	10.67	10.60	106	12.81	13.67	98	12.50	13.18	94	12.59	13.54	9.28(8)	0.32
Care-as-usual	..	..	..	109	13.91	14.35	106	13.13	14.36	98	14.20	14.86	87	11.59	12.48		
Fear of sexuality - FSQ fear of non-penetration sexual activity (0-20)	..	..	..	107	4.33	4.10	106	3.56	3.94	98	3.58	4.39	94	4.11	4.73	7.19(8)	0.51
Care-as-usual	..	..	..	109	3.83	4.10	106	3.40	3.83	98	3.30	3.80	87	3.32	4.30		
Fear of sexuality - FSQ fear of coitus/vaginal penetration (0-12)	..	..	..	107	1.65	2.52	106	1.65	2.26	98	1.45	2.16	94	1.90	2.61	2.41(8)	0.97
Care-as-usual	..	..	..	109	1.39	2.32	106	1.69	2.81	98	1.43	2.28	87	1.66	2.59		
Relationship dissatisfaction MMQ Marital scale	..	..	..	90	10.06	11.53	89	9.97	11.57	83	10.29	11.74	78	11.45	13.30	4.79(8)	0.78
Care-as-usual	..	..	..	84	11.76	15.35	80	10.75	12.44	72	10.08	9.58	66	10.85	11.16		
Psychological distress HADS Total (0-42)	..	..	..	107	9.95	7.30	105	9.87	7.14	98	9.46	7.33	94	8.93	7.74	5.87(8)	0.66
Care-as-usual	..	..	..	107	9.93	7.65	106	9.80	7.32	98	10.00	6.83	87	9.32	6.63		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	SD	%	N	SD	%	N	SD	%	N	SD	%	N	M/			SD
Psychological distress HADS depression (0-21)	..	..	..	107	4.22	3.68	105	4.13	3.89	98	3.87	3.62	94	3.47	3.79	5.96(8)	0.65
Intervention	..	..	..	107	4.36	4.03	106	4.01	3.86	98	4.21	3.64	87	3.41	3.36		
Care-as-usual	..	..	..	107	5.74	4.29	105	5.73	3.89	98	5.59	4.36	94	5.38	4.48	7.48(8)	0.49
Psychological distress HADS anxiety (0-21)	..	..	..	107	5.57	4.34	106	5.79	4.27	98	5.79	4.07	87	5.91	4.03		
Intervention	..	..	..	107	82.12	16.60	105	85.91	16.39	98	88.57	13.02	94	92.27	10.81	8.28(8)	0.41
Care-as-usual	..	..	..	109	81.22	16.89	106	86.04	14.59	98	88.10	13.17	86	91.32	11.57		
Physical function EORTC QLQ-C30 (0-100)	..	..	..	107	66.04	30.45	106	71.23	27.65	98	72.79	29.05	94	80.50	24.15	17.12(8)	0.03*
Intervention	..	..	..	109	66.67	25.36	106	69.81	25.73	98	75.17	23.96	87	82.95	23.29		
Care-as-usual	..	..	..	107	70.25	20.92	106	71.78	20.88	98	71.51	21.37	94	73.49	23.02	9.16(8)	0.33
Emotional function EORTC QLQ-C30 (0-100)	..	..	..	109	66.67	23.07	106	67.37	23.60	98	67.18	23.32	87	73.85	19.70		
Intervention	..	..	..	107	70.25	20.92	106	71.78	20.88	98	71.51	21.37	94	73.49	23.02		
Care-as-usual	..	..	..	109	66.67	23.07	106	67.37	23.60	98	67.18	23.32	87	73.85	19.70		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	SD	%	N	SD	%	N	SD	%	N	SD	%	N	SD			%
Cognitive function EORTC QLQ-C30 (0-100)	..	..	..	107	71.18	23.52	106	74.06	20.97	98	68.71	25.02	94	72.87	24.32	11.47(8)	0.18
Care-as-usual	..	..	..	109	68.65	24.19	106	70.44	23.15	98	72.11	25.19	87	76.05	23.80		
Social function EORTC QLQ-C30 (0-100)	..	..	..	107	67.76	27.31	106	73.74	25.09	98	76.53	24.27	94	83.51	19.48	9.7(8)	0.29
Care-as-usual	..	..	..	109	68.20	26.11	106	73.11	24.08	98	77.38	20.20	87	82.38	20.70		
Fatigue EORTC QLQ-C30 (0-100)	..	..	..	107	41.85	22.41	106	36.16	23.36	98	36.40	20.54	94	30.14	23.98	22.63(8)	0.004*
Care-as-usual	..	..	..	108	44.65	23.63	105	40.42	23.22	98	36.84	22.82	87	28.86	23.57		
Nausea/vomiting EORTC QLQ-C30 (0-100)	..	..	..	107	5.61	10.97	106	7.55	16.92	97	7.05	14.60	94	6.74	13.23	6.45(6)	0.38
Care-as-usual	..	..	..	109	8.26	12.75	106	5.35	14.47	98	5.61	10.42	87	4.02	8.79		
Pain EORTC QLQ-C30 (0-100)	..	..	..	107	20.09	20.57	106	19.18	21.18	97	20.96	23.97	94	16.67	22.0	6.34(8)	0.61
Care-as-usual	..	..	..	109	19.88	23.18	106	19.81	24.03	98	20.41	23.88	87	14.18	19.94		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %			SD
Dyspnoea EORTC QLQ-C30 (0-100)	..	..	..	107	17.45	23.50	106	11.95	17.33	98	9.18	18.40	94	10.28	20.75	3.23(8)	0.92
Care-as-usual	..	..	..	109	16.82	21.58	106	14.47	18.98	98	11.22	21.38	87	7.66	15.83		
Sleep disturbance EORTC QLQ-C30 (0-100)	..	..	..	107	36.14	29.0	106	32.39	31.02	98	31.63	29.65	94	30.14	31.71	9.71(8)	0.29
Care-as-usual	..	..	..	109	30.89	29.64	106	28.62	30.32	98	29.59	26.17	87	27.20	27.15		
Appetite loss EORTC QLQ-C30 (0-100)	..	..	..	107	9.66	15.87	106	10.06	19.61	98	8.84	18.88	94	6.74	16.0	1.82(6)	0.94
Care-as-usual	..	..	..	109	13.76	22.32	106	7.86	17.55	98	7.48	16.25	87	6.13	15.69		
Constipation EORTC QLQ-C30 (0-100)	..	..	..	107	10.28	18.55	106	10.06	18.50	97	12.72	21.75	94	10.28	18.31	1.53(8)	0.99
Care-as-usual	..	..	..	109	10.40	22.54	106	6.60	15.55	98	11.57	24.92	87	7.28	18.63		
Diarrhoea EORTC QLQ-C30 (0-100)	..	..	..	107	13.08	19.83	106	14.78	22.58	98	15.31	23.04	94	11.35	18.65	3.51(8)	0.90
Care-as-usual	..	..	..	109	19.57	24.52	106	17.61	26.11	98	18.37	23.02	87	12.64	19.85		

Table S3 *Continued*

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4				T5			
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD		N	M/ %	SD	LRT(df)
Financial impact EORTC QLQ-C30 (0-100)	..	..	..	107	12.46	23.58	106	13.21	23.76	98	11.91	20.45	94	11.35	21.06	2.9(8)	0.94
Intervention	..	..	..	109	15.60	25.49	106	11.01	22.41	98	10.20	20.54	87	14.18	25.74		
Care-as-usual	..	..	..	109	15.60	25.49	106	11.01	22.41	98	10.20	20.54	87	14.18	25.74		
Global QoL EORTC QLQ-C30 (0-100)	..	..	..	107	64.95	16.42	106	69.18	18.59	98	69.98	16.91	94	73.49	16.71	7.2(8)	0.51
Intervention	..	..	..	109	67.05	17.98	106	68.24	17.06	98	69.05	18.27	87	75.58	15.29		
Care-as-usual	..	..	..	109	67.05	17.98	106	68.24	17.06	98	69.05	18.27	87	75.58	15.29		
Gynaecological cancer treatment related stress IES Total (0-75)	..	..	..	107	24.09	16.61	105	20.05	15.83	98	19.12	16.46	94	17.49	16.24	6.03(8)	0.64
Intervention	..	..	..	107	24.24	17.33	106	21.65	16.06	98	20.95	15.93	87	18.66	16.10		
Care-as-usual	..	..	..	107	24.24	17.33	106	21.65	16.06	98	20.95	15.93	87	18.66	16.10		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %	SD	N	M/ %			SD
<b>Physician-assessed</b> Stenosis (shortening/ tightening) CTCAE Intervention	96	90.6	..	75	83.3	..	62	70.5	..	57	64.0	..	56	63.6	..	8.83(5)	0.12
<i>Grade 0</i>	8	7.5	..	11	12.2	..	20	22.7	..	26	29.2	..	21	23.9	..		
<i>Grade 1</i>	1	0.9	..	4	4.4	..	5	5.7	..	2	2.2	..	10	11.4	..		
<i>Grade 2</i>	1	0.9	..	0	0	..	1	1.1	..	4	4.5	..	1	1.1	..		
<i>Grade 3</i>																	
<b>Care-as-usual</b>	110	94.0	..	82	79.6	..	77	78.6	..	66	67.3	..	56	65.1	..		
<i>Grade 0</i>	4	3.4	..	19	18.4	..	14	14.3	..	22	22.4	..	20	23.3	..		
<i>Grade 1</i>	3	2.6	..	2	1.9	..	4	4.1	..	8	8.2	..	8	9.3	..		
<i>Grade 2</i>	0	0	..	0	0	..	3	3.1	..	2	2.0	..	2	2.3	..		
<i>Grade 3</i>																	
<b>Dryness CTCAE</b>																4.64(5)	0.46
Intervention	99	96.1	..	77	85.6	..	57	65.5	..	59	68.6	..	60	70.6	..		
<i>Grade 0</i>	2	1.9	..	12	13.3	..	20	23.0	..	17	19.8	..	18	21.2	..		
<i>Grade 1</i>	1	1.0	..	1	1.1	..	10	11.5	..	8	9.3	..	6	7.1	..		
<i>Grade 2</i>	1	1.0	..	0	0	..	0	0	..	2	2.3	..	1	1.2	..		
<i>Grade 3</i>																	
<b>Care-as-usual</b>	103	92.8	..	80	78.4	..	73	74.5	..	69	72.6	..	55	67.1	..		
<i>Grade 0</i>	4	3.6	..	19	18.6	..	24	24.5	..	24	25.3	..	26	31.7	..		
<i>Grade 1</i>	4	3.6	..	2	2.0	..	1	1.0	..	2	2.1	..	1	1.2	..		
<i>Grade 2</i>	0	0	..	1	1.0	..	0	0	..	0	0	..	0	0	..		
<i>Grade 3</i>																	

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4				T5			
	N	SD	%	N	SD	%	N	SD	%	N	SD	%		N	SD	%	LRT(df)
<b>Bleeding CTCAE Intervention</b>																	
<i>Grade 0</i>	47	42.3	..	94	87.0	..	81	86.2	..	76	82.6	..	78	83.0	..	7.6(5)	0.18
<i>Grade 1</i>	32	28.8	..	11	10.2	..	13	13.8	..	15	16.3	..	14	14.9	..		
<i>Grade 2</i>	26	23.4	..	3	2.8	..	0	0	..	1	1.1	..	2	2.1	..		
<i>Grade 3</i>	6	5.4	..	0	0	..	0	0	..	0	0	..	0	0	..		
<b>Care-as-usual</b>																	
<i>Grade 0</i>	51	43.6	..	102	91.1	..	88	81.5	..	78	77.2	..	72	80.0	..	11.04(5)	0.05*
<i>Grade 1</i>	32	27.4	..	10	8.9	..	19	17.6	..	22	21.8	..	17	18.9	..		
<i>Grade 2</i>	31	26.5	..	0	0	..	1	0.9	..	1	1.0	..	1	1.1	..		
<i>Grade 3</i>	3	2.6	..	0	0	..	0	0	..	0	0	..	0	0	..		
<b>Mucositis CTCAE Intervention</b>																	
<i>Grade 0</i>	104	97.2	..	51	53.1	..	68	74.7	..	74	86.0	..	72	80.9	..	11.04(5)	0.05*
<i>Grade 1</i>	3	2.8	..	41	42.7	..	21	23.1	..	10	11.6	..	13	14.6	..		
<i>Grade 2</i>	0	0	..	4	4.2	..	2	2.2	..	1	1.2	..	3	3.4	..		
<i>Grade 3</i>	0	0	..	0	0	..	0	0	..	1	1.2	..	1	1.1	..		
<i>Grade 4</i>	0	0	..	0	0	..	0	0	..	0	0	..	0	0	..		
<b>Care-as-usual</b>																	
<i>Grade 0</i>	111	95.7	..	54	50.9	..	68	71.6	..	81	84.4	..	70	82.4	..	11.04(5)	0.05*
<i>Grade 1</i>	4	3.4	..	46	43.4	..	21	22.1	..	12	12.5	..	13	15.3	..		
<i>Grade 2</i>	1	0.9	..	5	4.7	..	2	2.1	..	2	2.1	..	2	2.4	..		
<i>Grade 3</i>	0	0	..	1	0.9	..	3	3.2	..	1	1.0	..	0	0	..		
<i>Grade 4</i>	0	0	..	0	0	..	1	1.1	..	0	0	..	0	0	..		

Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4			T5		LRT(df)	P (overall model)	
	N	SD	M/ %	N	SD	M/ %	N	SD	M/ %	N	SD	M/ %	N	SD			M/ %
Discharge CTCAE																	
Intervention																	
Grade 0	73	67.0	..	57	53.8	..	60	64.5	..	66	73.3	..	65	70.7	..	1.65(5)	0.90
Grade 1	23	21.1	..	45	42.5	..	30	32.3	..	23	25.6	..	24	26.1	..		
Grade 2	13	11.9	..	4	3.8	..	3	3.2	..	1	1.1	..	3	3.3	..		
Grade 3	0	0	..	0	0	..	0	0	..	0	0	..	0	0	..		
Care-as-usual																	
Grade 0	70	61.4	..	56	50.5	..	66	63.5	..	69	70.4	..	62	68.9	..		
Grade 1	33	28.9	..	43	38.7	..	29	27.9	..	20	20.4	..	27	30.0	..		
Grade 2	11	9.6	..	12	10.8	..	9	8.7	..	9	9.2	..	1	1.1	..		
Grade 3	0	0	..	0	0	..	0	0	..	0	0	..	0	0	..		
Fibrosis CTCAE																	
Intervention																	
Grade 0	104	98.1	..	93	97.9	..	74	85.1	..	66	77.6	..	58	67.4	..	3.03(5)	0.70
Grade 1	2	1.9	..	2	2.1	..	13	14.9	..	18	21.2	..	25	29.1	..		
Grade 2	0	0	..	0	0	..	0	0	..	1	1.2	..	2	2.3	..		
Grade 3	0	0	..	0	0	..	0	0	..	0	0	..	1	1.2	..		
Care-as-usual																	
Grade 0	111	96.5	..	88	88.9	..	79	85.9	..	77	80.2	..	60	72.3	..		
Grade 1	3	2.6	..	11	11.1	..	13	14.1	..	15	15.6	..	22	26.5	..		
Grade 2	1	0.9	..	0	0	..	0	0	..	3	3.1	..	1	1.2	..		
Grade 3	0	0	..	0	0	..	0	0	..	1	1.0	..	0	0	..		


Table S3 Continued

Outcome measure (range score)	Assessment												GLMM outcomes				
	T1			T2			T3			T4				T5			
	N	SD	%	N	SD	%	N	SD	%	N	SD	%		N	SD	%	LRT(df)
Dyspareunia CTCAE Intervention																	
Grade 0	74	91.4	..	45	80.4	..	45	62.5	..	50	61.7	..	54	64.3	..	1.37(5)	0.93
Grade 1	3	3.7	..	9	16.1	..	21	29.2	..	24	29.6	..	24	28.6	..		
Grade 2	2	2.5	..	2	3.6	..	5	6.9	..	5	6.2	..	4	4.8	..		
Grade 3	2	2.5	..	0	0	..	1	1.4	..	2	2.5	..	2	2.4	..		
Care-as-usual																	
Grade 0	73	84.9	..	34	64.2	..	49	63.6	..	50	64.9	..	50	71.4	..		
Grade 1	10	11.6	..	15	28.3	..	18	23.4	..	17	22.1	..	14	20.0	..		
Grade 2	3	3.5	..	3	5.7	..	9	11.7	..	8	10.4	..	5	7.1	..		
Grade 3	0	0	..	1	1.9	..	1	1.3	..	2	2.6	..	1	1.4	..		

Note. CTCAE = Common Terminology Criteria for Adverse Events; df = degrees of freedom; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; EORTC QLQ-CX24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gynaecological Cancer Module; EORTC QLQ-EN24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module; FSDS = Female Sexual Distress Scale; FSFI = Female Sexual Function Index; FSQ = Fear of Sexuality Questionnaire; GLMM = Generalized Linear Mixed effects Model; HADS = Hospital Anxiety and Depression Scale; IES = Impact of Event Scale; IQR = interquartile range; M = mean; Md = median; MMQ = Maudsley Marital Questionnaire; N = observed number of women at the specific timepoint; QoL = Quality of Life; SD = standard deviation. \*p < 0.05.



**Figure S4** Physician-reported clinical measurements on single item level over time. The proportion of women is shown in percentages. BM = baseline measurement; CTCAE = Common Terminology Criteria for Adverse Events; M = months; N = number of women at risk at the specific timepoint; O = observed number of women at the specific timepoint.



**Figure S5** Patient-reported vaginal functioning problems on single item level over time. The proportion of women is shown in percentages. Figure I and IV only includes sexually active women. EORTC QLQ-CX24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Gynaecological Cancer Module; EORTC QLQ-EN24 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module; M = months; N = number of women at risk at the specific timepoint; n = number of sexually active women at risk at the specific timepoint according to EORTC QLQ-CX24 item 19; O = observed number of women at the specific timepoint.

**Table S6** The prevalence of women scoring at a clinical level on sexual functioning, sexual distress, relationship dissatisfaction, and psychological distress

	N	n cut-off*	% cut-off*
<b>Primary Outcome</b>			
FSFItotal BM			
Intervention (total group)	112	33	29.5
Care-as-usual (total group)	117	29	24.8
Sexually active	185	47	25.4
Not sexually active	42	14	33.3
Sexual intercourse	192	33	17.2
No sexual intercourse	35	28	80.0
FSFItotal 1M			
Intervention (total group)	108	80	74.1
Care-as-usual (total group)	110	82	74.5
Sexually active	128	79	61.7
Not sexually active	90	83	92.2
Sexual intercourse	84	38	45.2
No sexual intercourse	133	123	92.5
FSFItotal 3M			
Intervention (total group)	106	67	63.2
Care-as-usual (total group)	106	65	61.3
Sexually active	139	78	56.1
Not sexually active	73	54	74.0
Sexual intercourse	138	67	48.6
No sexual intercourse	74	65	87.8
FSFItotal 6M			
Intervention (total group)	98	49	50.0
Care-as-usual (total group)	98	54	55.1
Sexually active	128	59	46.1
Not sexually active	68	44	64.7
Sexual intercourse	134	48	35.8
No sexual intercourse	62	55	88.7
FSFItotal 12M			
Intervention (total group)	94	53	56.4
Care-as-usual (total group)	87	47	54.0
Sexually active	127	59	46.5
Not sexually active	54	41	75.9
Sexual intercourse	121	45	37.2
No sexual intercourse	60	55	91.7

Table S6 *Continued*

	N	n cut-off*	% cut-off*
<b>Secondary Outcomes</b>			
FSDStotal BM			
Intervention	112	29	25.9
Care-as-usual	117	30	25.6
FSDStotal 1M			
Intervention	107	54	50.5
Care-as-usual	110	49	44.5
FSDStotal 3M			
Intervention	106	49	46.2
Care-as-usual	106	45	42.5
FSDStotal 6M			
Intervention	98	43	43.9
Care-as-usual	98	46	46.9
FSDStotal 12M			
Intervention	94	42	44.7
Care-as-usual	87	40	46.0
MMQtotal 1M			
Intervention	90	13	14.4
Care-as-usual	84	16	19.0
MMQtotal 3M			
Intervention	89	16	18.0
Care-as-usual	80	15	18.8
MMQtotal 6M			
Intervention	83	17	20.5
Care-as-usual	72	11	15.3
MMQtotal 12M			
Intervention	78	15	19.2
Care-as-usual	66	13	19.7
HADStotal 1M			
Intervention	107	32	29.9
Care-as-usual	107	33	30.8
HADStotal 3M			
Intervention	105	33	31.4
Care-as-usual	106	27	25.5
HADStotal 6M			
Intervention	98	27	27.6
Care-as-usual	98	31	31.6
HADStotal 12M			
Intervention	94	21	22.3
Care-as-usual	87	21	24.1
HADS depression 1M			
Intervention	107	28	26.2
Care-as-usual	107	28	26.2

**Table S6** *Continued*

	<b>N</b>	<b>n cut-off*</b>	<b>% cut-off*</b>
HADS depression 3M			
Intervention	105	25	23.8
Care-as-usual	106	20	18.9
HADS depression 6M			
Intervention	98	22	22.4
Care-as-usual	98	21	21.4
HADS depression 12M			
Intervention	94	21	22.3
Care-as-usual	87	16	18.4
HADS anxiety 1M			
Intervention	107	41	38.3
Care-as-usual	107	38	35.5
HADS anxiety 3M			
Intervention	105	43	41.0
Care-as-usual	106	41	38.7
HADS anxiety 6M			
Intervention	98	37	37.8
Care-as-usual	98	35	35.7
HADS anxiety 12M			
Intervention	94	31	33.0
Care-as-usual	87	36	41.4

*Note.* BM = baseline measurement; FSFI = Female Sexual Function Index; FSIDS = Female Sexual Distress Scale; HADS = Hospital Anxiety and Depression Scale; M = months; MMQ = Maudsley Marital Questionnaire; N = observed number of women at the specific timepoint (for the MMQ, this number only includes women with a partner).

\* = women that scored above/below the clinical cut-off point.

## REFERENCES

1. Pieterse QD, Kenter GG, Maas CP, et al. Self-reported sexual, bowel and bladder function in cervical cancer patients following different treatment modalities: longitudinal prospective cohort study. *Int J Gynecol Cancer* 2013; **23**(9): 1717-25. doi:10.1097/IGC.0b013e3182a80a65.
2. Jensen PT, Groenvold M, Klee MC, Thranov I, Petersen MA, Machin D. Longitudinal study of sexual function and vaginal changes after radiotherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 2003; **56**(4): 937-49. doi:10.1016/s0360-3016(03)00362-6.
3. Abbott-Anderson K, Kwekkeboom KL. A systematic review of sexual concerns reported by gynecological cancer survivors. *Gynecologic Oncology* 2012; **124**(3): 477-89. doi:10.1016/j.ygyno.2011.11.030.
4. Kirchheiner K, Smet S, Jurgenliemk-Schulz IM, et al. Impact of Vaginal Symptoms and Hormonal Replacement Therapy on Sexual Outcomes After Definitive Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: Results from the EMBRACE-I Study. *Int J Radiat Oncol Biol Phys* 2022; **112**(2): 400-13. doi:10.1016/j.ijrobp.2021.08.036.
5. Roussin M, Lowe J, Hamilton A, Martin L. Factors of sexual quality of life in gynaecological cancers: a systematic literature review. *Arch Gynecol Obstet* 2021; **304**(3): 791-805. doi:10.1007/s00404-021-06056-0.
6. Damast S, Jeffery DD, Son CH, et al. Literature review of vaginal stenosis and dilator use in radiation oncology. *Pract Radiat Oncol* 2019; **9**(6): 479-91. doi:10.1016/j.prro.2019.07.001.
7. Robinson JW, Faris PD, Scott CB. Psychoeducational group increases vaginal dilation for younger women and reduces sexual fears for women of all ages with gynecological carcinoma treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 1999; **44**(3): 497-506. doi:10.1016/s0360-3016(99)00048-6.
8. Bakker RM, Vermeer WM, Creutzberg CL, Mens JWM, Nout RA, ter Kuile MM. Qualitative accounts of patients' determinants of vaginal dilator use after pelvic radiotherapy. *J Sex Med* 2015; **12**(3): 764-73. doi:10.1111/jsm.12776.
9. Hanlon A, Small W, Jr., Strauss J, et al. Dilator Use After Vaginal Brachytherapy for Endometrial Cancer: A Randomized Feasibility and Adherence Study. *Cancer Nurs* 2018; **41**(3): 200-9. doi:10.1097/NCC.0000000000000500.
10. Kozak MM, Usoz M, Fujimoto D, von Eyben R, Kidd E. Prospective randomized trial of email and/or telephone reminders to enhance vaginal dilator compliance in patients undergoing brachytherapy for gynecologic malignancies. *Brachytherapy* 2021; **20**(4): 788-95. doi:10.1016/j.brachy.2021.03.010.
11. Flynn P, Kew F, Kisely SR. Interventions for psychosexual dysfunction in women treated for gynaecological malignancy. *Cochrane Database Syst Rev* 2009; **2009**(2): CD004708. doi:10.1002/14651858.CD004708.pub2.
12. Huffman LB, Hartenbach EM, Carter J, Rash JK, Kushner DM. Maintaining sexual health throughout gynecologic cancer survivorship: A comprehensive review and clinical guide. *Gynecol Oncol* 2016; **140**(2): 359-68. doi:10.1016/j.ygyno.2015.11.010.
13. Scott JL, Halford WK, Ward BG. United we stand? The effects of a couple-coping intervention on adjustment to early stage breast or gynecological cancer. *J Consult Clin Psychol* 2004; **72**(6): 1122-35. doi:10.1037/0022-006x.72.6.1122.
14. Bakker RM, Mens JW, de Groot HE, et al. A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer. *Support Care Cancer* 2017; **25**(3): 729-37. doi:10.1007/s00520-016-3453-2.
15. Suvaal I, Hummel SB, Mens JM, et al. A sexual rehabilitation intervention for women with gynaecological cancer receiving radiotherapy (SPARC study): design of a multicentre randomized controlled trial. *BMC Cancer* 2021; **21**(1): 1295. doi:10.1186/s12885-021-08991-2.
16. Rakovshik SG, McManus F, Vazquez-Montes M, Muse K, Ougrin D. Is supervision necessary? Examining the effects of internet-based CBT training with and without supervision. *J Consult Clin Psychol* 2016; **84**(3): 191-9. doi:10.1037/ccp0000079.

17. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. *J Sex Marital Ther* 2000; **26**(2): 191-208. doi:10.1080/009262300278597.
18. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. *J Sex Marital Ther* 2005; **31**(1): 1-20. doi:10.1080/00926230590475206.
19. Derogatis LR, Rosen R, Leiblum S, Burnett A, Heiman J. The Female Sexual Distress Scale (FSDS): initial validation of a standardized scale for assessment of sexually related personal distress in women. *J Sex Marital Ther* 2002; **28**(4): 317-30. doi:10.1080/00926230290001448.
20. Greimel ER, Kuljanic Vlasic K, Waldenstrom AC, et al. The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module: EORTC QLQ-CX24. *Cancer* 2006; **107**(8): 1812-22. doi:10.1002/cncr.22217.
21. Cohen J. Statistical power analysis for the behavioral sciences 2nd ed. Mahwah, New Jersey: Lawrence Erlbaum Associates, Inc.; 1988.
22. Rizopoulos D. GLMMadaptive: Generalized Linear Mixed Models using Adaptive Gaussian Quadrature. R package version 0.8-2. 2021. <https://drizopoulos.github.io/GLMMadaptive/> (accessed 1st of June 2022).
23. (Olijf) DPAG. Living with cancer - Sexuality. 2021. <https://olijf.nl/leven-met-kanker/seksualiteit> (accessed May 26 2024).
24. Reed N, Balega J, Barwick T, et al. British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: recommendations for practice. *Eur J Obstet Gynecol Reprod Biol* 2021; **256**: 433-65. doi:10.1016/j.ejogrb.2020.08.020.
25. Integraal Kankercentrum Nederland. Cervixcarcinoom Landelijke richtlijn, Versie: 3.0. 2012. <http://www.med-info.nl/Richtlijnen/Oncologie/Gynaecologische%20tumoren/Cervixcarcinoom.pdf> (accessed 7th of December 2020).
26. Meyer-Bahlburg HFL, Dolezal C. The female sexual function index: a methodological critique and suggestions for improvement. *J Sex Marital Ther* 2007; **33**(3): 217-24. doi:10.1080/00926230701267852.
27. Kirchheiner K, Potter R, Tanderup K, et al. Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. *Int J Radiat Oncol Biol Phys* 2016; **94**(5): 1088-98. doi:10.1016/j.ijrobp.2015.12.363.
28. Jensen PT, Froeding LP. Pelvic radiotherapy and sexual function in women. *Transl Androl Urol* 2015; **4**(2): 186-205. doi:10.3978/j.issn.2223-4683.2015.04.06.
29. Suvaal I, Kirchheiner K, Nout RA, et al. Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy. *Gynecol Oncol* 2023; **170**: 123-32. doi:10.1016/j.ygyno.2023.01.005.
30. Kirchheiner K, Nout RA, Lindegaard JC, et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. *Radiother Oncol* 2016; **118**(1): 160-6. doi:10.1016/j.radonc.2015.12.025.